Big Pharma Looks to Ease Impact of Inflation Reduction Act

Big Pharma

Drugmakers are attempting to limit Medicare’s newfound ability to negotiate drug prices while also dealing with internal industry disputes and dwindling influence in Washington, D.C. Congress granted Medicare, the country’s largest buyer of prescription drugs, the authority to negotiate how much it pays for certain high-priced therapies and to receive rebates on treatments whose prices… Continue reading Big Pharma Looks to Ease Impact of Inflation Reduction Act